Melbourne medicinal cannabis company debuts on the ASX with $19.65m IPO

Melbourne medicinal cannabis company debuts on the ASX with $19.65m IPO

There's certainly no shortage of medicinal cannabis stocks to invest in on the ASX, and with today's listing of Althea (ASX: AGH) we're certainly spoilt for choice.

The Melbourne-based medicinal cannabis company launched on the ASX on Friday morning after a hugely successful and heavily oversubscribed IPO of $19.65 million.

Althea, which specialises in importing, cultivating, producing and supplying medicinal cannabis for eligible patients across Australia issued 98.25 million new shares at $0.20 per share during the IPO, giving the company a market cap of $40.6 million on listing.

Althea has been supplying patients in Australia since May, making it the first Aussie company to do so.

Thanks to its strategic partnership with Canadian giant Aphira, Althea commenced importing and supplying five Althea branded medicinal products to eligible patients in cannabis oil and dried flower form back in May.

Aphira, one of the largest medicinal cannabis companies listed on the Toronto Stock Exchange, took a cornerstone position in the IPO, and now holds 25 per cent in Althea.

CEO and MD of Althea, Joshua Fegan, says the company is hyper-focused on patients outcomes.

"Our aim is to educate and support patient access to medicinal cannabis in Australia," says Fegan.

"Our measured three-stage growth plan supports Althea's vision to become a leading and trusted medicinal cannabis brand in Australia."

READ: The Cannabis Index: A complete guide to cannabis stocks on the ASX

Althea's three-stage business model involves early revenue generation, sales driven growth, and scalable domestic production.

The company has even engaged a team of medical science liaisons who are working to assist medical practitioners to become prescribers, and pharmacists to become suppliers, of Althea products.

The company will put the $19.65 million raised in the IPO toward brand awareness initiatives, and fund the design, construction, and commissioning and completion of a 4,080sqm medicinal cannabis cultivation, extraction and manufacturing facility in Skye, Victoria. The facility is expected to product approximately 3 tonnes of cannabis each year.

"Looking ahead, we intend to double down on our medical education program and leverage technology to build a greater understanding of medicinal cannabis for patients and healthcare professionals through Althea Concierge, our web-based platform and free-to-download mobile app," says Fegan.

Get our daily business news

Sign up to our free email news updates.

Please tick to verify that you are not a robot

 

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Australian Millennial managers look to offshoring to solve global talent shortage problem
Partner Content
New research reveals that more than half of Australia’s next-gen leaders are cons...
Cloudstaff
Advertisement

Related Stories

Musk, Wozniak, tech leaders sign open letter calling for pause on “out-of-control” AI development

Musk, Wozniak, tech leaders sign open letter calling for pause on “out-of-control” AI development

An open letter signed by more than 1,000 artificial intelligen...

Zip Co pulls the plug on Central and Eastern Europe, South Africa

Zip Co pulls the plug on Central and Eastern Europe, South Africa

Zip Co (ASX: ZIP) will exit its offices in Prague and Johannesburg ...

HealthCo raising $320m to fund $1.2b acquisition of Healthscope hospitals

HealthCo raising $320m to fund $1.2b acquisition of Healthscope hospitals

HealthCo Healthcare and Wellness REIT (ASX: HCW), a property invest...

US giant Sentinel grows its Australian build-to-rent portfolio with a first for Adelaide

US giant Sentinel grows its Australian build-to-rent portfolio with a first for Adelaide

US property giant Sentinel Real Estate Corporation has expanded its...